United States securities and exchange commission logo





                          August 18, 2020

       Sergio Traversa
       Chief Executive Officer
       Relmada Therapeutics, Inc.
       880 Third Avenue, 12th Floor
       New York, NY 10022

                                                        Re: Relmada
Therapeutics, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed August 12,
2020
                                                            File No. 333-245054

       Dear Mr. Traversa:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Deanna
Virginio at 202-551-4530 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Barrett DiPaolo, Esq.